GSK plc (GLAXF)
- Previous Close
18.00 - Open
18.00 - Bid 18.00 x 45100
- Ask 18.95 x 40000
- Day's Range
18.00 - 18.00 - 52 Week Range
15.54 - 23.00 - Volume
54 - Avg. Volume
2,477 - Market Cap (intraday)
78.348B - Beta (5Y Monthly) 0.27
- PE Ratio (TTM)
18.56 - EPS (TTM)
1.01 - Earnings Date Jul 30, 2025
- Forward Dividend & Yield 0.86 (4.59%)
- Ex-Dividend Date May 15, 2025
- 1y Target Est
--
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, infectious, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, inflammation, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop vaccines for influenza and COVID-19, as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom.
www.gsk.com68,629
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: GLAXF
View MorePerformance Overview: GLAXF
Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GLAXF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GLAXF
View MoreValuation Measures
Market Cap
74.85B
Enterprise Value
93.48B
Trailing P/E
18.54
Forward P/E
8.33
PEG Ratio (5yr expected)
0.37
Price/Sales (ttm)
1.86
Price/Book (mrq)
4.05
Enterprise Value/Revenue
2.22
Enterprise Value/EBITDA
9.10
Financial Highlights
Profitability and Income Statement
Profit Margin
10.00%
Return on Assets (ttm)
6.55%
Return on Equity (ttm)
27.09%
Revenue (ttm)
31.53B
Net Income Avi to Common (ttm)
3.15B
Diluted EPS (ttm)
1.01
Balance Sheet and Cash Flow
Total Cash (mrq)
4.49B
Total Debt/Equity (mrq)
134.99%
Levered Free Cash Flow (ttm)
5.16B